Company news

Share this article:
Valeant Pharmaceuticals has announced a definitive agreement to acquire Dow Pharmaceutical Sciences, a privately held dermatology company, for $285 million. Dow Pharmaceutical Sciences' current annualized revenues are approximately $45 million, of which roughly $20 million represents royalty payments from licensed products.
 
Wyeth will cut 276 workers in Puerto Rico as a result of decreasing demand for locally manufactured products. The layoffs will be completed by February 2009, with 2,700 workers remaining across three plants in the US Caribbean territory, the AP reported.
 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.